Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
February 11, 2019
AIT Therapeutics Announces Appointment of Robert F. Carey to Board of Directors
GARDEN CITY, N.Y. and REHOVOT, Israel, Feb. 11, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on ...
February 11, 2019
CohBar Announces the Appointment of Dr. Phyllis Gardner to its Board of Directors
MENLO PARK, Calif., Feb. 11, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related ...
February 11, 2019
Kiadis Pharma to participate in a panel at Innovation for Health 2019
Amsterdam, The Netherlands, February 11, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today ...
February 11, 2019
Genkyotex Announces Award of Grant from Cancer Research UK to Academic Partner to Further Develop NOX Research in Oncology
Genkyotex (GKTX.PA) (GKTX.PA) (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today that Professor Gareth Thomas ...
February 7, 2019
Basilea announces change in the Management Committee - Adesh Kaul appointed CFO
Basel, February 7, 2019 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that the Board of Directors has appointed Adesh Kaul, currently Chief Corporate Development Officer ...
February 7, 2019
AC Immune Makes Two Appointments to Executive Committee to Accelerate Product Development
LAUSANNE, Switzerland, Feb. 07, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, ...
February 7, 2019
InspireMD to Report Fourth Quarter and Fiscal 2018 Financial Results and Provide Business Update on Tuesday, February 19
TEL AVIV, Israel, Feb. 07, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention ...
February 7, 2019
Equillium Granted U.S. FDA Orphan Drug Designations for EQ001 (itolizumab) for both the Prevention and Treatment of Acute Graft-Versus-Host Disease
LA JOLLA, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the ...
February 7, 2019
OSE Immunotherapeutics and Servier Announce First Option Within Global License Agreement Exercised for Further Clinical Development and Potential Commercialisation of OSE-127 in Autoimmune Diseases
NANTES, France and PARIS, Feb. 07, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), today announced that Servier, an independent international pharmaceutical company, ...
February 7, 2019
Check-Cap Ltd. Announces Closing of $7.5 Million Registered Direct Offering
ISFIYA, Israel, Feb. 7, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (CHEKZ), a clinical-stage medical diagnostics company offering C-Scan®, the first ...
February 7, 2019
BioLineRx Announces Closing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants
TEL AVIV, Israel, Feb. 8, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has closed ...
February 7, 2019
Arrowhead Pharmaceuticals Reports Fiscal 2019 First Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (ARWR) today announced financial results for its fiscal 2019 first quarter ended December 31, 2018. The company is hosting a ...
February 7, 2019
OncoCyte Announces Proposed Public Offering of Common Stock
ALAMEDA, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) (“OncoCyte”), a developer of novel, non-invasive liquid biopsy tests for the early ...
February 7, 2019
Arena Pharmaceuticals Presents Preclinical and Early Clinical Development Data for Olorinab at Crohn's & Colitis Congress
SAN DIEGO, Feb. 7, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) will present preclinical and early clinical development data from its investigative drug candidate olorinab, a ...
February 7, 2019
Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day
SAN DIEGO, Feb. 7, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical-stage targeted oncology company, will participate in the Guggenheim Healthcare Talks Idea Forum & ...
February 7, 2019
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2018
HOUSTON, TX and VANCOUVER, Feb. 7, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on ...
February 6, 2019
Novelion Therapeutics Subsidiary Enters Into Licensing Agreement for JUXTAPID® in Japan
VANCOUVER, British Columbia, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with ...
February 6, 2019
Kamada Announces Additional Interim Results from Phase 2 Proof of Concept Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection
REHOVOT, Israel, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced ...
February 6, 2019
InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa
JENA, Germany and NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- InflaRx N.V. (IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases ...
February 6, 2019
Orchard Therapeutics Announces Acceptance of Late-Breaking Abstracts of OTL-101 for ADA-SCID and OTL-102 for X-CGD at the 2019 Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR
BOSTON and LONDON, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with ...
Page 26 of 150